MyQuest™

RIGLIETTI,ROBERT

DOB: 07/30/1995
Sex: M
Phone: (631) 793-2551
Patient ID: 1109

Age: 30
Fasting: N

Specimen: ZD998285F
Requisition: 0000799
Lab Reference ID: 4399
Report Status: FINAL

Collected: 08/15/2025 15:03
Received: 08/15/2025 15:05
Reported: 08/22/2025 12:41

Client #: 91436084
SHILIAN,RYAN
ALLERGY IMMUNOLOGY CTR
STE 409
16661 VENTURA BLVD
ENCINO, CA 91436-1914
Phone: (818) 514-3544
Fax: (818) 578-0298

FASTING:NO

STREPTOCOCCUS PNEUMONIAE AB (IGG) (23 SEROTYPES)

Analyte	Value
SEROTYPE 1 (1)	48.6
SEROTYPE 2 (2)	86.1
SEROTYPE 3 (3)	12.8
SEROTYPE 4 (4)	2.7
SEROTYPE 5 (5)	>154.0
SEROTYPE 8 (8)	>86.0
SEROTYPE 9 (9N)	>41.0
SEROTYPE 12 (12F)	5.0
SEROTYPE 14 (14)	1.3
SEROTYPE 17 (17F)	30.6
SEROTYPE 19 (19F)	17.1
SEROTYPE 20 (20)	22.6
SEROTYPE 22 (22F)	14.1
SEROTYPE 23 (23F)	0.8
SEROTYPE 26 (6B)	5.7
SEROTYPE 34 (10A)	2.3
SEROTYPE 43 (11A)	10.1
SEROTYPE 51 (7F)	30.2
SEROTYPE 54 (15B)	17.0
SEROTYPE 56 (18C)	12.2
SEROTYPE 57 (19A)	16.5
SEROTYPE 68 (9V)	25.3

SEROTYPE 70 (33F)	**>47.0**

Serologic correlates of protection against pneumococcal disease have not been rigorously established for all patient populations. Published data and expert consensus (including WHO) suggest protection from invasive disease usually occurs at levels >or =0.3-0.50 mcg/mL for healthy children receiving pneumococcal conjugate vaccines. Higher titers may be necessary to protect from non-invasive infection (e.g., pneumonia, otitis, sinusitis). Expert opinion suggests that a cut-off of >= 1.3 mcg/mL may be a more relevant value to assess antibody responses after pneumococcal polysaccharide vaccines or for immunocompromised patients. In addition to antibody quantity, protection also depends on antibody avidity and opsonophagocytic activity. Some experts consider that post-vaccination (4-6 weeks) IgG seroconversion and/or 2- to 4-fold rise in IgG titers for >50% to 70% of vaccine serotypes demonstrates a normal post-vaccine serologic response. Persons with high initial serotype-specific titers may have less robust responses.

Quest Diagnostics uses a multi-analyte immunodetection (MAID) method. The method employs the Luminex flow cytometric system which measures multiple analytes simultaneously. The FDA standard reference serum 89-S is used as the calibration standard. Results are reported in mcg/mL.

This assay detects all of the 23 of the serotypes in the 23-valent polysaccharide vaccine and 12 of the 13 serotypes in the 13-valent conjugate vaccine.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and used for clinical purposes.

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ181 (This link is being provided for informational/ educational purposes only.)

Performing Sites

EZ Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Laboratory Director: Irina Maramica MD,PhD,MBA

Key

Priority Out of Range Out of Range